Keywords: Gilead Sciences, Emtricitabine-based ARVs, Developing countries, Manufacturing, Mylan, Ranbaxy, Strides Arcolab, Low prices
Gilead partners to provide low-cost emtricitabine-based ARVs in developing countries
Article | 03 August 2012
Gilead Sciences (Nasdaq: GILD), together with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab have entered into agreements to collaborate on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
